Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 23

1.

Reply to Hunsberger and Memoli, "Efficacy Analysis in Healthy-Volunteer Influenza Challenge Trials: Intention To Treat".

McBride JM, Lim JJ, Burgess T, Deng R, Derby MA, Maia M, Horn P, Siddiqui O, Sheinson D, Chen-Harris H, Newton EM, Fillos D, Nazzal D, Rosenberger CM, Ohlson MB, Lambkin-Williams R, Fathi H, Harris JM, Tavel JA.

Antimicrob Agents Chemother. 2017 Dec 21;62(1). pii: e02034-17. doi: 10.1128/AAC.02034-17. Print 2018 Jan. No abstract available.

2.

Phase 2 Randomized Trial of the Safety and Efficacy of MHAA4549A, a Broadly Neutralizing Monoclonal Antibody, in a Human Influenza A Virus Challenge Model.

McBride JM, Lim JJ, Burgess T, Deng R, Derby MA, Maia M, Horn P, Siddiqui O, Sheinson D, Chen-Harris H, Newton EM, Fillos D, Nazzal D, Rosenberger CM, Ohlson MB, Lambkin-Williams R, Fathi H, Harris JM, Tavel JA.

Antimicrob Agents Chemother. 2017 Oct 24;61(11). pii: e01154-17. doi: 10.1128/AAC.01154-17. Print 2017 Nov.

3.

Pharmacokinetics of MHAA4549A, an Anti-Influenza A Monoclonal Antibody, in Healthy Subjects Challenged with Influenza A Virus in a Phase IIa Randomized Trial.

Deng R, Lee AP, Maia M, Lim JJ, Burgess T, Horn P, Derby MA, Newton E, Tavel JA, Hanley WD.

Clin Pharmacokinet. 2018 Mar;57(3):367-377. doi: 10.1007/s40262-017-0564-y.

PMID:
28639229
4.

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single-Ascending-Dose Study To Investigate the Safety, Tolerability, and Pharmacokinetics of an Anti-Influenza B Virus Monoclonal Antibody, MHAB5553A, in Healthy Volunteers.

Lim JJ, Derby MA, Zhang Y, Deng R, Larouche R, Anderson M, Maia M, Carrier S, Pelletier I, Girard J, Kulkarni P, Newton E, Tavel JA.

Antimicrob Agents Chemother. 2017 Jul 25;61(8). pii: e00279-17. doi: 10.1128/AAC.00279-17. Print 2017 Aug.

5.

Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial of RG7667, a Combination Monoclonal Antibody, for Prevention of Cytomegalovirus Infection in High-Risk Kidney Transplant Recipients.

Ishida JH, Patel A, Mehta AK, Gatault P, McBride JM, Burgess T, Derby MA, Snydman DR, Emu B, Feierbach B, Fouts AE, Maia M, Deng R, Rosenberger CM, Gennaro LA, Striano NS, Liao XC, Tavel JA.

Antimicrob Agents Chemother. 2017 Jan 24;61(2). pii: e01794-16. doi: 10.1128/AAC.01794-16. Print 2017 Feb.

6.

Two Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single-Ascending-Dose Studies To Investigate the Safety, Tolerability, and Pharmacokinetics of an Anti-Influenza A Virus Monoclonal Antibody, MHAA4549A, in Healthy Volunteers.

Lim JJ, Deng R, Derby MA, Larouche R, Horn P, Anderson M, Maia M, Carrier S, Pelletier I, Burgess T, Kulkarni P, Newton E, Tavel JA.

Antimicrob Agents Chemother. 2016 Aug 22;60(9):5437-44. doi: 10.1128/AAC.00607-16. Print 2016 Sep.

7.

Phase 1 Randomized, Double-Blind, Placebo-Controlled Study of RG7667, an Anticytomegalovirus Combination Monoclonal Antibody Therapy, in Healthy Adults.

Ishida JH, Burgess T, Derby MA, Brown PA, Maia M, Deng R, Emu B, Feierbach B, Fouts AE, Liao XC, Tavel JA.

Antimicrob Agents Chemother. 2015 Aug;59(8):4919-29. doi: 10.1128/AAC.00523-15. Epub 2015 Jun 8.

8.

The effects of supratherapeutic doses of duloxetine on blood pressure and pulse rate.

Derby MA, Zhang L, Chappell JC, Gonzales CR, Callaghan JT, Leibowitz M, Ereshefsky L, Hoelscher D, Leese PT, Mitchell MI.

J Cardiovasc Pharmacol. 2007 Jun;49(6):384-93.

PMID:
17577103
9.

Neuropsychological practice effects and change detection in people with schizophrenia.

Beglinger LJ, Ahmed S, Derby MA, Siemers E, Fastenau PS, Crawford-Miller J, Shekhar A, Kareken DA.

Schizophr Res. 2003 Jul 1;62(1-2):191-4. No abstract available.

PMID:
12765761
10.

An abrupt and concordant initiation of apoptosis: antigen-dependent death of CD8+ CTL.

Derby MA, Snyder JT, Tse R, Alexander-Miller MA, Berzofsky JA.

Eur J Immunol. 2001 Oct;31(10):2951-9.

11.

Competitive inhibition in vivo and skewing of the T cell repertoire of antigen-specific CTL priming by an anti-peptide-MHC monoclonal antibody.

Chung DH, Belyakov IM, Derby MA, Wang J, Boyd LF, Berzofsky JA, Margulies DH.

J Immunol. 2001 Jul 15;167(2):699-707.

12.

Two intermediate-avidity cytotoxic T lymphocyte clones with a disparity between functional avidity and MHC tetramer staining.

Derby MA, Wang J, Margulies DH, Berzofsky JA.

Int Immunol. 2001 Jun;13(6):817-24.

PMID:
11369710
13.

Approaches to improve engineered vaccines for human immunodeficiency virus and other viruses that cause chronic infections.

Berzofsky JA, Ahlers JD, Derby MA, Pendleton CD, Arichi T, Belyakov IM.

Immunol Rev. 1999 Aug;170:151-72. Review.

PMID:
10566149
14.

Interaction of murine MHC class I molecules with tapasin and TAP enhances peptide loading and involves the heavy chain alpha3 domain.

Suh WK, Derby MA, Cohen-Doyle MF, Schoenhals GJ, Früh K, Berzofsky JA, Williams DB.

J Immunol. 1999 Feb 1;162(3):1530-40.

16.

Mucosal immunization with HIV-1 peptide vaccine induces mucosal and systemic cytotoxic T lymphocytes and protective immunity in mice against intrarectal recombinant HIV-vaccinia challenge.

Belyakov IM, Derby MA, Ahlers JD, Kelsall BL, Earl P, Moss B, Strober W, Berzofsky JA.

Proc Natl Acad Sci U S A. 1998 Feb 17;95(4):1709-14.

17.
18.

Monoclonal antibodies against a differentiated retinal cell population.

Derby MA, Dyer SA, Glaser L.

Brain Res. 1983 Apr;283(2-3):317-25.

PMID:
6850355
20.
21.
22.

The histochemical specificity of Streptomyces hyaluronidase and chondroitinase ABC.

Derby MA, Pintar JE.

Histochem J. 1978 Sep;10(5):529-47.

PMID:
80394
23.

The morphogenesis of spinal ganglia from neural crest cells.

Weston JA, Pintar JE, Derby MA, Nichols DH.

Prog Clin Biol Res. 1977;15:217-26. No abstract available.

PMID:
928453

Supplemental Content

Loading ...
Support Center